BeOne Medicines (NASDAQ:ONC) Insider Sells $310,240.91 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Lai Wang sold 1,169 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $265.39, for a total transaction of $310,240.91. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lai Wang also recently made the following trade(s):

• On Thursday, June 11th, Lai Wang sold 756 shares of BeOne Medicines stock. The stock was sold at an average price of $261.00, for a total transaction of $197,316.00.
• On Monday, June 8th, Lai Wang sold 1,367 shares of BeOne Medicines stock. The stock was sold at an average price of $269.38, for a total transaction of $368,242.46.

BeOne Medicines Price Performance

Shares of ONC opened at $270.15 on Friday. The firm has a market cap of $29.64 billion, a PE ratio of 60.44 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a fifty day simple moving average of $295.32 and a two-hundred day simple moving average of $312.15. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current year.

Institutional Trading of BeOne Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fiera Capital Corp lifted its position in shares of BeOne Medicines by 20.1% during the 3rd quarter. Fiera Capital Corp now owns 25,117 shares of the company’s stock valued at $8,557,000 after buying an additional 4,205 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in BeOne Medicines by 100.6% in the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after acquiring an additional 97,244 shares in the last quarter. Slow Capital Inc. increased its holdings in BeOne Medicines by 51.5% in the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after acquiring an additional 9,280 shares in the last quarter. Generali Investments Management Co LLC purchased a new stake in BeOne Medicines in the 3rd quarter worth approximately $2,726,000. Finally, Capital International Sarl raised its stake in BeOne Medicines by 2.7% during the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock worth $46,336,000 after acquiring an additional 3,956 shares during the period. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

ONC has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Jefferies Financial Group lowered shares of BeOne Medicines from a “buy” rating to a “hold” rating and reduced their price target for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Leerink Partners increased their price objective on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. Wall Street Zen cut shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Royal Bank Of Canada raised their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, BeOne Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $390.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.